Skip to content
AnalystLens

DEXCOM INC 8-K Report, Financial Results (Oct 24, 2024)

Reports
Earnings & Results·Exhibits & Filings
Filing Date
Filed October 24, 2024
Period End
October 24, 2024
Security
DXCM
In the record · 2016–202610-K1110-Q328-K134

DXCM filed 11 annual reports (10-K), 32 quarterly reports (10-Q) and 134 current reports (8-K) between 2016 and 2026.

  1. Material agreement8-K · May ’17May ’17
  2. Material agreement8-K · May ’20May ’20
  3. Leadership change8-K · Aug ’22Aug ’22
  4. Leadership change8-K · Sep ’26Sep ’26

01—Abstract

Summary

Summary of the 8-K filed October 24, 2024. Cited figures are marked; the original filing is the authoritative source.

DexCom reported third-quarter 2024 revenue of $994.2 milliona, up 2% year over year on a reported basis and 3% on an organic basis.

Growth was driven by international markets, where revenue rose 12% reported (16% organic), while U.S. revenue fell 2% to $701.9 millionb. Profitability declined sharply: GAAP operating income was $152.0 million (15.3% margin), down 580 basis points, and non-GAAP operating income was $212.0 million (21.3% margin), down 320 basis points. Non-GAAP gross margin fell to 63.0% from 64.7%, and non-GAAP diluted EPS was $0.45 versus $0.50.

Hardware revenue fell 58% to $42.4 millionc, and the company recorded a non-recurring $24.6 million non-cash inventory build charge in the quarter. DexCom reiterated its full-year 2024 guidance of revenue of $4.00 to $4.05 billion (11% to 13% organic growth), non-GAAP gross margin of about 63%, non-GAAP operating margin of about 20%, and Adjusted EBITDA margin of about 29%. Implied fourth-quarter performance will need to be meaningfully stronger than the third quarter to reach these targets, given that nine-month revenue was $2.92 billion.

Capital allocation remained active: the company executed a $750 milliond share repurchase program, reducing treasury share counts and diluted shares to 410.2 million from 426.8 million year over year, and it ended the quarter with $2.49 billion in cash and marketable securities and an undrawn revolver. Strategically, DexCom launched Stelo, its over-the-counter CGM for adults with prediabetes or type 2 diabetes not on insulin, and submitted its Dexcom G7 15-day CGM system to the FDA for review.

Leadership is also changing: Chief Commercial Officer Teri Lawver will retire at year-end, and Chairman, President and CEO Kevin Sayer will lead the commercial organization pending a global search for a successor. The filing is furnished under Item 2.02, so the press release is not deemed filed under the Exchange Act.

02—Key points

Key Highlights

  1. Revenue of $994.2 million grew 2% reported (3% organic), with international revenue up 12% and U.S. revenue down 2%.
  2. Margin compression: GAAP operating margin fell to 15.3% (down 580 bps) and non-GAAP operating margin to 21.3% (down 320 bps), with non-GAAP gross margin at 63.0% versus 64.7%.
  3. Non-GAAP diluted EPS of $0.45 declined from $0.50, while GAAP diluted EPS rose to $0.34 from $0.29, largely due to lower tax expense.
  4. Full-year 2024 guidance reiterated: revenue of $4.00 to $4.05 billion and Adjusted EBITDA margin of about 29%, which requires a stronger fourth quarter.
  5. Executed a $750 million share repurchase; cash and marketable securities of $2.49 billion and an undrawn revolver provide flexibility.
  6. Launched Stelo, the first over-the-counter glucose biosensor in the U.S., and submitted the G7 15-day CGM to the FDA.
  7. Chief Commercial Officer Teri Lawver will retire at year-end; the CEO will oversee commercial operations during a global search for a successor.

03—Questions

Frequently Asked Questions

  1. Is DexCom on track to meet its 2024 revenue guidance?

    Management reiterated revenue guidance of $4.00 to $4.05 billion. Nine-month revenue was $2.92 billion, so the company needs roughly $1.08 to $1.13 billion in fourth-quarter revenue, above the $994.2 million reported in the third quarter. Achieving this would require a clear acceleration in the fourth quarter.

  2. Why did profitability decline even though revenue grew?

    Non-GAAP gross margin fell to 63.0% from 64.7%, and operating expenses grew faster than revenue. Hardware revenue dropped 58%, and the quarter included a non-recurring $24.6 million non-cash inventory build charge. Non-GAAP operating income declined to $212.0 million from $238.9 million.

  3. How is the U.S. business performing compared with international?

    U.S. revenue declined 2% to $701.9 million, representing 71% of total revenue. International revenue grew 12% reported and 16% organic to $292.3 million, indicating that international expansion is currently offsetting domestic weakness.

  4. What does the $750 million buyback mean for shareholders?

    The repurchase reduced diluted weighted-average shares to 410.2 million from 426.8 million year over year, which supports per-share results. The company retains $2.49 billion in cash and marketable securities, though it also carries about $2.44 billion in long-term convertible notes.

  5. What are the key near-term catalysts and leadership changes?

    Near-term catalysts include the FDA review of the Dexcom G7 15-day CGM and the ramp of Stelo, the over-the-counter biosensor. The chief commercial officer, Teri Lawver, will retire at year-end, and CEO Kevin Sayer will lead commercial operations while the company searches for a replacement, which introduces execution risk during the transition.

04—Continue

← View all 8-K filings